TY - JOUR
T1 - Influence of Mild Cognitive Impairment on LSVT® BIG Therapy Effectiveness in People with Parkinson’s Disease
T2 - A Retrospective Cohort Study
AU - Iwai, Masanobu
AU - Sakurai, Hiroaki
AU - Koyama, Soichiro
AU - Takeda, Kazuya
AU - Hirakawa, Yuichi
AU - Motoya, Ikuo
AU - Kanada, Yoshikiyo
AU - Okada, Yohei
AU - Kawamura, Nobutoshi
AU - Kawamura, Mami
AU - Tanabe, Shigeo
N1 - Publisher Copyright:
© 2024 Taylor & Francis Group, LLC.
PY - 2024
Y1 - 2024
N2 - Aim: To investigate the influence of cognitive functions on the effectiveness of Lee Silverman Voice Treatment (LSVT)® BIG therapy on motor symptoms, gait speed, activities of daily living (ADLs), and quality of life (QOL) in people with Parkinson’s disease (PD). Methods: This retrospective, single-center cohort study included 20 people with PD (PwPD) with mild cognitive impairment (PD-MCI group) or without (PD-NC group) (n = 10 each). Results: In the PD-NC group, all assessments improved significantly. Similarly, the PD-MCI group showed significant improvements in the total Movement Disorder Society‐sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III, 10-meter walking test, and total MDS-UPDRS Part II. However, the Parkinson’s Disease Questionnaire summary index showed a trend toward improvement that did not reach statistical significance. Conclusions: LSVT® BIG therapy may improve motor symptoms, gait speed, and ADLs in PwPD, regardless of the presence or absence of MCI.
AB - Aim: To investigate the influence of cognitive functions on the effectiveness of Lee Silverman Voice Treatment (LSVT)® BIG therapy on motor symptoms, gait speed, activities of daily living (ADLs), and quality of life (QOL) in people with Parkinson’s disease (PD). Methods: This retrospective, single-center cohort study included 20 people with PD (PwPD) with mild cognitive impairment (PD-MCI group) or without (PD-NC group) (n = 10 each). Results: In the PD-NC group, all assessments improved significantly. Similarly, the PD-MCI group showed significant improvements in the total Movement Disorder Society‐sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III, 10-meter walking test, and total MDS-UPDRS Part II. However, the Parkinson’s Disease Questionnaire summary index showed a trend toward improvement that did not reach statistical significance. Conclusions: LSVT® BIG therapy may improve motor symptoms, gait speed, and ADLs in PwPD, regardless of the presence or absence of MCI.
KW - ADL
KW - cognitive impairment
KW - gait speed
KW - motor symptom
UR - http://www.scopus.com/inward/record.url?scp=85210008536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85210008536&partnerID=8YFLogxK
U2 - 10.1080/02703181.2024.2430221
DO - 10.1080/02703181.2024.2430221
M3 - Article
AN - SCOPUS:85210008536
SN - 0270-3181
JO - Physical and Occupational Therapy in Geriatrics
JF - Physical and Occupational Therapy in Geriatrics
ER -